Pfister Chemical, Inc.

Pfister Chemical, Inc. requests a process and reaction exclusion under 40 CFR 766.32(a)(1)(ii) for 3,4',5-Tribromosalicylanilide (CAS No. 87–10–5) and an economic waiver under 40 CFR 766.32(a)(2)(ii) for the same chemical.

The Agency denies Pfister's request for a process exclusion for 3,4',5-Tribromosalicylanilide. The Agency based its analysis on Pfister's specific process and reaction conditions as described by the company for this chemical and other data available to the Agency. These data indicate the potential for dioxin formation.

In addition, the Agency denies Pfister's request for an economic waiver for 3,4',5-Tribromosalicylanilide. The Agency agrees, based on the cost and production data supplied by Pfister, that testing costs may be large enough to drive this chemical off the market. However, Pfister failed to provide any information that would alter the Agency's assessment of risk for the final rule as required for an economic waiver. In the rulemaking record, EPA found that chemicals subject to the rule may present an unreasonable risk such that testing at the specified levels is required. Chemicals contaminated even with trace levels of 2,3,7 8-substituted HDDs/HDFs may be toxic.

Pfister indicated in its submission that 3,4',5–Tribromosalicylanilide is used in consumer products such as paints, detergents, and cleaners. The Agency finds that the potential risks of this chemical, particularly from its presence in consumer products, outweighs the economic burden of testing and, therefore, justifies the requirement to test.

Sigma Chemical Company

Sigma Chemical Company requests a research and development waiver under 40 CFR 766.32(a)(2)(i) for four chemicals and a process and reaction exclusion under 40 CFR 766.32(a)(1)(ii) for one chemical.

The Agency grants Sigma's request for a research and development waiver for two of four chemicals Sigma identified as being imported. However, should Sigma produce these chemicals in quantities above 100 kilograms per year in the future, the Agency requires that Sigma report this to the Agency and comply with the requirements of the rule for such chemicals.

Sigma identified the remaining two chemicals as domestically procured, processed and resold. Under the rule, [40 CFR 766.20(a)] Sigma is considered a processor of these chemicals and, therefore, is not subject to the testing and reporting requirements. However, if manufacturers or importers of these substances fail to sponosr testing, the Agency will issue a **Federal Register** notice informing processors of that chemical substance(s). Processors will then have 30 days to submit either a letter of intent to test or an exemption application.

Regarding Sigma's process and reaction exclusion request for 2,4-Dichlorophenol (CAS No. 120–83–2), the Agency considers Sigma a processor and, therefore, not subject to the testing and reporting requirements of the rule. However, if manufacturers or importers of this substance fail to sponsor testing, the Agency will issue a **Federal Register** notice informing processors of that chemical substance(s). Processors will then have 30 days to submit either a letter of intent to test or an exemption application.

Finally, the Agency regrets the inadvertent omission of 2,3,5,6-Tetrachloro-2,5-cyclohexadiene-1,4-dione from Sigma's waiver request published in the **Federal Register** of November 10, 1987 (52 FR 43250).

III. Public Record

The Agency received no coments on any of the seven companies' exclusion and/or waiver requests.

The Agency has prepared a public version of an administrative file containing documents supporting these decisions. However, much of the analysis is not available in the public docket because it is based on confidential business information.

Dated: February 2, 1988.

Martin P. Halper,

Director, Exposure Evaluation Division.

[FR Doc. 88–2807 Filed 2–9–88; 8:45 am]

BILLING CODE 6560–50–M

FEDERAL COMMUNICATIONS COMMISSION

Applications for Consolidated Hearing; Douglas Gaines Harding et al.

1. The Commission has before it the following mutually exclusive applications for a new FM station:

Applicant, city and state	File No.	MM Docket No.
A. Douglas Gaines Harding; Shepherdsville, KY.	BPH–860311MH	88–4
B. Bullitt Broadcasting; Shepherdsville, KY.	BPH–860313MO	.....
C. John D. Harper; Shepherdsville, KY.	BPH–860314MI	.....
D. Julie N. Frew; Shepherdsville, KY.	BPH–860317MT	.....
E. Gene R. Osselmeier; Shepherdsville, KY.	BPH–860317MV	.....
F. Claire Tow; Shepherdsville, KY.	BPH–860317MW	.....
G. Don H. Barden; Shepherdsville, KY.	BPH–860317MX	.....

2. Pursuant to section 309(e) of the Communications Act of 1934, as amended, the above applications have been designated for hearing in a consolidated proceeding upon the issues whose headings are set forth below. The text of each of these issues has been standardized and is set forth in its entirety under the corresponding headings at 51 FR 19347, May 29, 1986. The letter shown before each applicant's name, above, is used below to signify whether the issue in question applies to that particular applicant.

Issue Heading and Applicants.

1. Air Hazard, A
2. Comparative, All
3. Ultimate, All

3. If there is any non-standardized issue(s) in this proceeding, the full text of the issue and the applicant(s) to which it applies are set forth in an Appendix to this Notice. A copy of the complete HDO in this proceeding is available for inspection and copying during normal business hours in the FCC Dockets Branch (Room 230), 1919 M Street, NW., Washington, DC. The complete text may also be purchased from the Commission's duplicating contractor, International Transcription Services, Inc., 2100 M Street, N.W., Washington, DC. 20037. (Telephone (202) 857–3800).

W. Jan Gay,

Assistant Chief, Audio Services Division, Mass Media Bureau.

[FR Doc. 88–2743 Filed 2–9–88; 8:45 am]

BILLING CODE 6712–01–M

Applications for Consolidated Hearing; Taylor Broadcasting Inc., et al.

1. The Commission has before it the following mutually exclusive applications for a new FM station:

Applicant, city and State	File No.	MM Docket No.
A. Taylor Broadcasting, Inc.; Bedford, N.H.	BPH–860714MA	88–3

Applicant, city and State	File No.	MM Docket No.
B. Colonial Communications, Inc.; Bedford, N.H.	BPH-860801MB	.....
C. Kirkley Paige Beal; Bedford, N.H.	BPH-860801MC	.....
D. Michael J. Hughes; Bedford, N.H.	BPH-860804MA	.....
E. Susan R. Beauchamp; Bedford, N.H.	BPH-860804MB	.....
F. Satellite Systems Engineering Inc.; Bedford, N.H.	BPH-860804MD	.....
G. Bedford Concepts, a California Limited Partnership; Bedford, N.H.	BPH-860804ME	.....
H. Donna M. MacNeil; Bedford, N.H.	BPH-860804MF	.....
I. Benjamin Macwan; Bedford, N.H.	BPH-860804MG	.....
J. Susan Tucker *et al.*, d/b/a Interstate Communications; Bedford, N.H.	BPH-860804MH	.....
K. Appledore Communications, Inc.; Bedford, N.H.	BPH-860804MI	.....
L. Bedford Radio Broadcasting Corporation; Bedford, N.H.	BPH-860804MO	.....
M. Airwave Communications, Inc.; Bedford, N.H.	BPH-860804MP	.....
N. Bedford Broadcasting Limited Partnership; Bedford, N.H.	BPH-860804MS	.....
O. Vernon C. Floyd; Bedford, N.H.	BPH-860804MQ	(Dismissed).

2. Pursuant to section 309(e) of the Communications Act of 1934, as amended, the above applications have been designated for hearing in a consolidated proceeding upon the issues whose headings are set forth below. The next of each of these issues has been standardized and is set forth in its entirety under the corresponding headings at 51 FR 19347, May 29, 1986. The letter shown before each applicant's name above is used below to signify whether the issue is question applies to that particular applicant.

Issue Heading and Applicant(s)

1. Comparative, All Applicants
2. Ultimate, All Applicants

3. If there is any non-standardized issue(s) in this proceeding, the full text of the issue and the applicant(s) to which it applies are set forth in an Appendix to this Notice. A copy of the complete HDO in this proceeding is available for inspection and copying during normal business hours in the FCC Dockets Branch (Room 230), 1919 M Street NW., Washington, DC. The complete text may also be purchased from the Commission's duplicating contractor, International Transcription Services, Inc., 2100 M Street NW., Washington, DC 20037 (Telephone No. (202) 857-3800).

W. Jan Gay,

Assistant Chief, Audio Services Division, Mass Media Bureau.

[FR Doc. 88-2744 Filed 2-9-88; 8:45 am]

BILLING CODE 6712-01-M

FEDERAL MARITIME COMMISSION

Agreement(s) Filed

The Federal Commission hereby gives notice of the filing of the following agreement(s) pursuant to section 5 of the Shipping Act of 1984.

Interested parties may inspect and obtain a copy of each agreement at the Washington, DC Office of the Federal Maritime Commission, 1100 L Street NW., Room 10325. Interested parties may submit comments on each agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, within 10 days after the date of the **Federal Register** in which this notice appears. The requirements for comments are found in § 572.603 of Title 46 of the Code of Federal Regulations. Interested persons should consult this section before communicating with the Commission regarding a pending agreement.

Agreements No.:

(1) 202-000093-041
(2) 202-005200-054

Titles:

(1) North Europe-U.S. Pacific Freight Conference

(2) Pacific Coast European Conference

Parties (1) & (2):

Hapag-Lloyd AG
Johnson Scanstar
Compagnie Generale Maritime
Incotrans BV
Sea-Land Service, Inc.

Synopsis: The proposed amendments would specifically permit the parties to negotiate agreements with European inland carriers on transportation costs which are part of the member lines through transportation responsibility.

Agreement No.: 203-011117-001.

Title: North America-Australasia Interconference and Carrier Discussion Agreement.

Parties:

Pacific Coast/Australia-New Zealand Tariff Bureau
U.S. Atlantic & Gulf/Australia-New Zealand Conference
Blue Star Line Ltd.
Pacific Australia Direct Line
Associated Container Transportation (Australia) Ltd.

Synopsis: The proposed amendment would delete Shipping Corporation of New Zealand Limited as a party to the agreement and would add as parties Australia-New Zealand Direct Line and Ocean Star Line, A.G.

Agreement No.: 202-011137-002.

Title: Pacific Coast/Australia-New Zealand Tariff Bureau Discussion Agreement.

Parties:

Pacific Coast/Australia-New Zealand Tariff Bureau
Hong Kong Islands Line America S.A.
Leif Heogh & Co., A.S.

Synopsis: The proposed amendment would add Nedlloyd Lines as a party to the agreement and would delete Canada from the agreement's geographic scope. The parties have requested a shortened review period.

By Order of the Federal Maritime Commission.

Joseph C. Polking,

Secretary.

Dated: February 5, 1988.

[FR Doc. 88-2831 Filed 2-9-88; 8:45 am]

BILLING CODE 6730-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 87F-0417]

Insta Cool Inc. of North America; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Insta Cool Inc. of North America has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a mixture of fluorocarbon 113 and perfluorohexane to quickly chill whole chickens sealed in poly-bags.

FOR FURTHER INFORMATION CONTACT: Eric Flamm, Center for Food Safety and Applied Nutrition (HFF-334), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202-426-8950.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 7A4039) has been filed by Insta Cool Inc. of North America, 3235 Sunrise Blvd., Suite C, Rancho Cardova, CA 95670, proposing that 21 CFR Part 173—Secondary Direct Food Additives Permitted in Food for Human

Consumption be amended to provide for the safe use of a mixture of fluorocarbon 113 and perfluorohexane to quickly chill whole chickens sealed in poly-bags.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register**, in accordance with 21 CFR 25.40(c).

Dated: January 29, 1988.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 88-2756 Filed 2-9-88; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 88M-0005]

IVAC® Corp.; Premarket Approval of the IVAC® Titrator™ Sodium Nitroprusside Closed Loop Module—Model 10K

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by IVAC® Corp., San Diego, CA, for premarket approval, under the Medical Device Amendments of 1976, of the IVAC® Titrator™ Sodium Nitroprusside Closed Loop Module—Model 10K. After reviewing the recommendation of the General Hospital and Personal Use Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant of the approval of the application.

DATE: Petitions for administrative review by March 11, 1988.

ADDRESS: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: George S. Mills, Center for Devices and Radiological Health (HFZ-420), Food and Drug Administration, 8757 Georgia Ave., Silver Spring, MD 20910, 301-427-7750.

SUPPLEMENTARY INFORMATION: On December 30, 1986, IVAC® Corp., San Diego, CA 92138-5335, submitted to CDRH an application for premarket approval of the IVAC® Titrator™ Sodium Nitroprusside Closed Loop Module—Model 10K. The device is a microprocessor unit that controls the IVAC® closed loop sodium nitroprusside (SNP) regulating system. The IVAC® Titrator™ Sodium Nitroprusside Closed Loop Module—Model 10K, hereinafter referred to as the Titrator™, is indicated for use in adult patients who require an infusion of sodium nitroprusside to control blood pressure following cardiovascular surgery. SNP is a hypotensive agent used to control blood pressure. The Titrator™ measures the patient's mean arterial blood pressure and, based on any deviation between the patient's pressure and the physician's prescribed blood pressure setpoint, adjusts the SNP infusion rate to return the patient's blood pressure to the blood pressure setpoint. The external infusion pump, infusion set, IV catheter and transducer portions of the IVAC® closed loop SNP regulating system are pre-Amendment devices or have previously been determined to be substantially equivalent to other pre-Amendment devices and consequently do not require premarket approval.

On April 6, 1987, the General Hospital and Personal Use Devices Panel, an FDA advisory committee, reviewed and recommended approval of the application. On December 17, 1987, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file with the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

A copy of all approved labeling is available for public inspection at the CDRH—contact George S. Mills (HFZ-420), address above.

Opportunity For Administrative Review

Section 515(d)(3) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition under section 515(g) of the act (21 U.S.C. 360e(g)) for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under Part 12 (21 CFR Part 12) of FDA's administrative practices and procedures regulations or a review of the application and of CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish notice of its decision in the **Federal Register**. If FDA grants the petition, the notice will state the issue to be reviewed, the form of review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before March 11, 1988, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h), 90 Stat. 554-555, 571 (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: February 2, 1988.

John C. Villforth,

Director, Center for Devices and Radiological Health.

[FR Doc. 88-2758 Filed 2-9-88; 8:45 am]

BILLING CODE 4160-01-M

Consumer Participation; Open Meeting

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the following district consumer exchange meeting: New Orleans District Office, chaired by Robert O. Bartz, District Director. The topices to be discussed are cholesterol labeling and health claims on food labels.

DATE: Wednesday, February 24, 1988, 11 a.m.

ADDRESS: Southern University, School of Nursing Auditorium, Swan Ave., Baton Rouge, LA 70813.

FOR FURTHER INFORMATION CONTACT: Barbara Loyd, Consumer Affairs Officer, Food and Drug Administration, 4298